|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,462.80 INR | -0.01% |
|
+0.31% | -3.18% |
| 08-11 | Global drugmakers invest billions to boost US presence | RE |
| 07-28 | Cipla Limited Receives U.S. Fda Approval for Generic Advair Diskus | CI |
Company Valuation: Cipla Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 821,377 | 726,839 | 1,208,588 | 1,164,745 | 988,887 | 1,181,885 | - | - |
| Change | - | -11.51% | 66.28% | -3.63% | -15.1% | 19.52% | - | - |
| Enterprise Value (EV) 1 | 810,334 | 716,397 | 1,154,239 | 1,084,736 | 901,599 | 1,075,811 | 1,050,441 | 1,034,049 |
| Change | - | -11.59% | 61.12% | -6.02% | -16.88% | 19.32% | -2.36% | -1.56% |
| P/E | 32.7x | 26x | 29.3x | 22.1x | 25.5x | 28.5x | 23x | 20.4x |
| PBR | 3.94x | 3.11x | 4.53x | 3.73x | 2.87x | 3.15x | 2.85x | 2.58x |
| PEG | - | 2.3x | 0.6x | 0.8x | -1x | 4.06x | 1x | 1.6x |
| Capitalization / Revenue | 3.77x | 3.19x | 4.69x | 4.23x | 3.51x | 3.81x | 3.4x | 3.11x |
| EV / Revenue | 3.72x | 3.15x | 4.48x | 3.94x | 3.2x | 3.47x | 3.02x | 2.72x |
| EV / EBITDA | 17.8x | 14.3x | 18.3x | 15.2x | 15.3x | 18x | 14.3x | 12.5x |
| EV / EBIT | 23.1x | 18.6x | 22x | 18x | 19.3x | 23.1x | 17.6x | 15.2x |
| EV / FCF | 29.1x | 29.9x | 38x | 28.2x | 38.5x | 38x | 28.5x | 24.8x |
| FCF Yield | 3.43% | 3.35% | 2.63% | 3.54% | 2.6% | 2.63% | 3.51% | 4.03% |
| Dividend per Share 2 | 5 | 8.5 | 13 | 13 | 13 | 12.99 | 14.73 | 14.28 |
| Rate of return | 0.49% | 0.94% | 0.87% | 0.9% | 1.06% | 0.89% | 1.01% | 0.98% |
| EPS 2 | 31.17 | 34.69 | 51.01 | 65.24 | 48 | 51.37 | 63.72 | 71.84 |
| Distribution rate | 16% | 24.5% | 25.5% | 19.9% | 27.1% | 25.3% | 23.1% | 19.9% |
| Net sales 1 | 217,633 | 227,531 | 257,741 | 275,476 | 281,626 | 309,889 | 347,298 | 379,577 |
| EBITDA 1 | 45,528 | 50,270 | 62,910 | 71,279 | 58,829 | 59,803 | 73,604 | 82,600 |
| EBIT 1 | 35,008 | 38,549 | 52,400 | 60,210 | 46,719 | 46,645 | 59,576 | 68,102 |
| Net income 1 | 25,168 | 28,019 | 41,216 | 52,725 | 38,792 | 41,350 | 51,420 | 57,963 |
| Net Debt 1 | -11,043 | -10,443 | -54,350 | -80,010 | -87,289 | -106,073 | -131,444 | -147,836 |
| Reference price 2 | 1,018.05 | 900.50 | 1,496.95 | 1,442.20 | 1,224.20 | 1,463.00 | 1,463.00 | 1,463.00 |
| Nbr of stocks (in thousands) | 806,814 | 807,151 | 807,367 | 807,617 | 807,783 | 807,850 | - | - |
| Announcement Date | 5/10/22 | 5/12/23 | 5/10/24 | 5/13/25 | 5/13/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 28.57x | 3.48x | 18.05x | 0.89% | 12.39B | |
| 35.88x | 6.74x | 23.35x | 0.88% | 48.85B | |
| 19.79x | 2.33x | 10.61x | 1.31% | 41.43B | |
| 26.53x | 3.91x | 15.94x | 0.6% | 12.46B | |
| 18.73x | 3.33x | 11.58x | 3.85% | 9.08B | |
| 8.96x | 2.07x | 5.39x | 4.49% | 7.53B | |
| 15.92x | 2.06x | 6.44x | 3.24% | 7.14B | |
| 34.17x | 3.89x | 16.56x | 0.23% | 6.73B | |
| 41.82x | 8.01x | 29.72x | 0.95% | 4.59B | |
| Average | 25.60x | 3.98x | 15.29x | 1.83% | 16.69B | |
| Weighted average by Cap. | 26.83x | 4.27x | 16.26x | 1.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CIPLA Stock
- Valuation Cipla Limited
Select your edition
All financial news and data tailored to specific country editions
